Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Bertoletti (St Priest En Jarez, France). Evolution of DLNO/DLCO ratio after initiation of targeted PH therapy in naïve patients.. 2399

Member's Comments

No comment yet.

Related content which might interest you: Economic impact of delayed multiple-inhaler triple therapy initiation in COPD patients Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Using remote directly observed therapy (R-DOT) for optimising asthma therapy. Source: International Congress 2017 – Small airways, long distances and large databases in paediatric asthma Year: 2017 Optimizing the target therapy development Source: ERS Research Seminar Year: 2015 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 COPD exacerbation: resolution of symptoms after starting antibiotic treatment was unaltered by the timing of therapy but was dependent on baseline gas transfer Source: Annual Congress 2008 - Management of COPD Year: 2008 Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS) Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Prediction of long-term effect of anti-angiogenic therapy in lung cancer patients by monitoring early changes in circulating-tumor DNA (ctDNA). Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020 Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future? Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments Year: 2019 Defining the role of neutrophil-to-lymphocyte ratio in COPD patients Source: Virtual Congress 2020 – Prognosis and integrated management of COPD Year: 2020 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Non-invasive ventilation as a first-line treatment for malaria patients with pulmonary dysfunction: A feature of respiratory therapy. Source: International Congress 2018 – New tools for managing respiratory failure Year: 2018 Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004 Patterns of drug resistance at initiation of re-treatment across relapse, default and failure subcategories in previously treated tubercular patients Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 Impact of tidal volume, GAP index and anti-fibrotic treatment on disease progression and mortality in IPF patients Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with advanced HIV disease Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Characteristics of glucose metabolism in patients receiving glucocorticoid therapy for interstitial lung disease. Source: International Congress 2017 – Miscellaneous clinical problems Year: 2017 Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021